The Global Cough
Suppressant Drugs Market, by Disease Type (Dry Cough and Wet Cough), by
Drug Type (Dextromethorphan, Codeine, Noscapine, Butamirate, Benzonatate,
Pholcodine, and Others), by Product Type (Over-the-counter (OTC) and
Prescription Drug), by Age Group (Pediatric and Adult), by Dosage Form (Syrup,
Tablet, and Others), by Distribution Channel (Hospital, Retail Pharmacy, Online
Pharmacy, and Others), and by Region (North America, Latin America, Europe,
Asia Pacific, Middle East, and Africa), was valued at US$ 1100.4 Mn in 2017 and
is projected to exhibit a CAGR of 3.7% during the forecast period (2018–2026).
Frequent approvals and launch of
new cough suppressant drugs is expected to drive the global cough suppressant
drugs market growth over the forecast period. For instance, in 2017, Aurobindo
Pharma Limited received the U.S. Food & Drug Administration (FDA) approval
for its Guaifenesin and Dextromethorphan Hydrobromide extended-release tablets,
600/30 mg and 1200/60mg (OTC) indicated to loosen mucus and phlegm, and thin
out bronchial secretions, making coughs more productive. Aurobindo’s
Guaifenesin and Dextromethorphan Hydrobromide extended-release tablets are the
generic equivalent of Reckitt Benckiser’s Mucinex DM tablets. Such approval and
launch of new cough suppressant drugs in the market is expected to drive the
global cough suppressant drugs market growth over the forecast period.
Browse 42 Market Data Tables and
40 Figures spread through 175 Pages and in-depth TOC on Global Cough
Suppressant Drugs Market, by Disease Type (Dry Cough and Wet Cough), by Drug
Type (Dextromethorphan, Codeine, Noscapine, Butamirate, Benzonatate,
Pholcodine, and Others), by Product Type (Over-the-counter (OTC) and
Prescription Drug), by Age Group (Pediatric and Adult), by Dosage Form (Syrup,
Tablet, and Others), by Distribution Channel (Hospital, Retail Pharmacy, Online
Pharmacy, and Others), and Region (North America, Latin America, Europe, Asia
Pacific, Middle East, and Africa) - Global Forecast to 2026.
* The sample copy includes: Report Summary, Table of
Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/2427
Some stringent regulations
against the use of cough suppressant drugs is expected to hinder the global
drug suppressant drugs market growth over the forecast period. For instance, in
January 2018, FDA introduced a regulation, which inhibits the use of
codeine-based cough suppressant drugs in children less than 18 years of age. In
August 2018, the Colorado introduced a law, which prohibits the sales of
over-the-counter (OTC) medicines containing the cough suppressant
dextromethorphan (DXM) to minors and in 2017, Health Canada proposed to ban
non-prescription cough suppressant drug codeine sales in 2017. Such regulations
that limits the sales and adoption of cough suppressant drugs is expected to
affect the market growth.
Key Takeaways of the Cough
Suppressant Drugs Market:
The global cough suppressant
drugs market is expected to exhibit a CAGR of 3.7% during the forecast period
(2018 – 2026), owing to frequent product launches and approvals, and robust
pipeline of novel cough suppressant drugs
Key players in the market are
adopting strategies such as mergers and partnership for the development,
manufacturing, and marketing of new cough suppressant drugs. For instance, in
2012, Vernalis plc, a U.K.-based development stage pharmaceutical company, and
Tris Pharma Inc., a U.S.-based specialty pharmaceutical company, entered into
an exclusive license agreement for the development and commercialization of
multiple novel products focused on the U.S. prescription cough/cold market.
Browse Research
Report: https://www.coherentmarketinsights.com/market-insight/cough-suppressant-drugs-market-2427
Approval and launch of new cough
suppressant drugs in the U.S. is expected to drive growth of the North America
cough suppressant drugs market during the forecast period
Asia Pacific cough suppressant
drugs market is expected to show good growth over the forecast period, owing to
high prevalence of cough in countries such as India and China. For instance,
according to the data published by Journal of the Association of Physicians of
India in 2016, it was estimated that around 54% of the population in India
suffers from cough
Major players operating in the
global cough suppressant drugs market include Perrigo Company plc, Vernalis
plc. Tris Pharma Inc., Pfizer Inc., Aytu BioScience, Inc., Acella
Pharmaceuticals LLC, Mayne Pharma Inc., Taro Pharmaceutical Industries Ltd.,
Amneal Pharmaceuticals LLC, Aurobindo Pharma Ltd, and GlaxoSmithKline plc.
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/2427
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar
opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN
: +050-5539-1737
No comments:
Post a Comment